Skip to main content
SpringerLink
Log in

Immune-mediated cholangitis: is it always nivolumab’s fault?

  • Letter to the Editors
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

A Letter to the Editors to this article was published on 26 April 2018

The Original Article was published on 14 September 2017

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Kashima J, Okuma Y, Shimizuguchi R, Chiba K (2018) Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report. Cancer Immunol Immunother 67:61–65. https://doi.org/10.1007/s00262-017-2062-3

    Article  PubMed  Google Scholar 

  2. Kawakami H, Tanizaki J, Tanaka K et al (2017) Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer. Invest New Drugs 35:529–536

    Article  PubMed  CAS  Google Scholar 

  3. Gelsomino F, Vitale G, D’Errico A, Bertuzzi C, Andreone P, Ardizzoni A (2017) Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury. Ann Oncol 28:671–672

    Article  PubMed  CAS  Google Scholar 

  4. European Association for the Study of the Liver (2009) EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 51:237–267

    Article  Google Scholar 

  5. Haanen JBAG., Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, ESMO Guidelines Committee (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 28(suppl_4):iv119-iv142

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Medical Oncology Unit, Policlinico S. Orsola-Malpighi, University of Bologna, Via Albertoni 15, 40138, Bologna, Italy

    Francesco Gelsomino, Giovanni Vitale & Andrea Ardizzoni

Authors
  1. Francesco Gelsomino
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giovanni Vitale
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Andrea Ardizzoni
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Francesco Gelsomino.

Ethics declarations

Conflict of interest

All authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gelsomino, F., Vitale, G. & Ardizzoni, A. Immune-mediated cholangitis: is it always nivolumab’s fault?. Cancer Immunol Immunother 67, 1325–1327 (2018). https://doi.org/10.1007/s00262-018-2159-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00262-018-2159-3

Search

Navigation